Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19
Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people. In the absence of an approved, recognized effe...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | One Health |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352771420300628 |
_version_ | 1818958526837424128 |
---|---|
author | Stephane Picot Aileen Marty Anne-Lise Bienvenu Lucille H. Blumberg Jean Dupouy-Camet Pierre Carnevale Shigeyuki Kano Malcolm K. Jones Cláudio Tadeu Daniel-Ribeiro Santiago Mas-Coma |
author_facet | Stephane Picot Aileen Marty Anne-Lise Bienvenu Lucille H. Blumberg Jean Dupouy-Camet Pierre Carnevale Shigeyuki Kano Malcolm K. Jones Cláudio Tadeu Daniel-Ribeiro Santiago Mas-Coma |
author_sort | Stephane Picot |
collection | DOAJ |
description | Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people. In the absence of an approved, recognized effective pre or post-exposure prophylactic drug or vaccine for COVID-19, nor of any approved and validated therapeutic drug, coupled with social and political pressure raised by publicity both regarding the potential beneficial effect of hydroxychloroquine (HCQ) as well as potential risks from HCQ, we urge the immediate proper clinical trials. Specifically, we mean using HCQ for post-exposure of people with close contact with patients with positive COVID19 rtPCR, including home and medical caregivers. We have reviewed the mechanisms of antiviral effect of HCQ, the risk-benefit ratio taking into consideration the PK/PD of HCQ and the thresholds of efficacy. We have studied its use as an antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of HCQ at doses matching that of the standard treatment of Systemic Lupus erythematous, which has proven safety and efficacy in terms of HCQ blood and tissue concentration adapted to bodyweight (2,3), at 6 mg/kg/day 1 (loading dose) followed by 5 mg/kg/ day, with a maximum limit of 600 mg/day in all cases should swiftly be clinically evaluated as a post-exposure drug for exposed people. Keywords: COVID19, SARS-CoV2, Hydroxychloroquine, Chloroquine, Systemic lupus erythematosus, Immunomodulation, Coronavirus, malaria, antiviral |
first_indexed | 2024-12-20T11:27:09Z |
format | Article |
id | doaj.art-1e54fceee7414c1589c100bc6a7423fc |
institution | Directory Open Access Journal |
issn | 2352-7714 |
language | English |
last_indexed | 2024-12-20T11:27:09Z |
publishDate | 2020-06-01 |
publisher | Elsevier |
record_format | Article |
series | One Health |
spelling | doaj.art-1e54fceee7414c1589c100bc6a7423fc2022-12-21T19:42:19ZengElsevierOne Health2352-77142020-06-019Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19Stephane Picot0Aileen Marty1Anne-Lise Bienvenu2Lucille H. Blumberg3Jean Dupouy-Camet4Pierre Carnevale5Shigeyuki Kano6Malcolm K. Jones7Cláudio Tadeu Daniel-Ribeiro8Santiago Mas-Coma9Malaria Research Unit, ICBMS, UMR 5246, CNRS, INSA, CPE University Lyon, 69100 Villeurbanne, France; Institute of Parasitology and Medical Mycology, Croix-Rousse Hospital, Hospices Civils de Lyon, 69004 Lyon, France; Corresponding author at: ICBMS CNRS 5246, Campus Lyon-Tech La Doua, Université de Lyon, Villeurbanne 69100, France.Translational Medicine, HWCOM, FIU Health Travel Medicine Program and Vaccine Clinic Commander, Emergency Response Team Development, Miami, FL, United StatesMalaria Research Unit, ICBMS, UMR 5246, CNRS, INSA, CPE University Lyon, 69100 Villeurbanne, France; Groupement Hospitalier Nord, Service Pharmacie, Hospices Civils de Lyon, 69004 Lyon, FranceDivision of Public Health Surveillance and Response, National Institute for Communicable Diseases, 2131 Johannesburg, South AfricaFaculté de Médecine Paris Descartes, Académie Vétérinaire de France, Paris, FranceInstitute of Research for Development (former), Montpellier Centre, BP 64501, 34394 Montpellier, FranceDepartment of Tropical Medicine and Malaria, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, JapanSchool of Veterinary Science, The University of Queensland, Brisbane, QLD, AustraliaLaboratório de Pesquisa em Malária, Instituto Oswaldo Cruz & Centro de Pesquisa de Diagnóstico e Treinamento, Fiocruz. Av. Brasil 4365. CEP 21.040-360, Rio de Janeiro, Brazil.Departamento de Parasitología, Facultad de Farmacia, Universidad de Valencia, 46100, Valencia, SpainOur coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people. In the absence of an approved, recognized effective pre or post-exposure prophylactic drug or vaccine for COVID-19, nor of any approved and validated therapeutic drug, coupled with social and political pressure raised by publicity both regarding the potential beneficial effect of hydroxychloroquine (HCQ) as well as potential risks from HCQ, we urge the immediate proper clinical trials. Specifically, we mean using HCQ for post-exposure of people with close contact with patients with positive COVID19 rtPCR, including home and medical caregivers. We have reviewed the mechanisms of antiviral effect of HCQ, the risk-benefit ratio taking into consideration the PK/PD of HCQ and the thresholds of efficacy. We have studied its use as an antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of HCQ at doses matching that of the standard treatment of Systemic Lupus erythematous, which has proven safety and efficacy in terms of HCQ blood and tissue concentration adapted to bodyweight (2,3), at 6 mg/kg/day 1 (loading dose) followed by 5 mg/kg/ day, with a maximum limit of 600 mg/day in all cases should swiftly be clinically evaluated as a post-exposure drug for exposed people. Keywords: COVID19, SARS-CoV2, Hydroxychloroquine, Chloroquine, Systemic lupus erythematosus, Immunomodulation, Coronavirus, malaria, antiviralhttp://www.sciencedirect.com/science/article/pii/S2352771420300628 |
spellingShingle | Stephane Picot Aileen Marty Anne-Lise Bienvenu Lucille H. Blumberg Jean Dupouy-Camet Pierre Carnevale Shigeyuki Kano Malcolm K. Jones Cláudio Tadeu Daniel-Ribeiro Santiago Mas-Coma Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19 One Health |
title | Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19 |
title_full | Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19 |
title_fullStr | Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19 |
title_full_unstemmed | Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19 |
title_short | Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19 |
title_sort | coalition advocacy for prospective clinical trials to test the post exposure potential of hydroxychloroquine against covid 19 |
url | http://www.sciencedirect.com/science/article/pii/S2352771420300628 |
work_keys_str_mv | AT stephanepicot coalitionadvocacyforprospectiveclinicaltrialstotestthepostexposurepotentialofhydroxychloroquineagainstcovid19 AT aileenmarty coalitionadvocacyforprospectiveclinicaltrialstotestthepostexposurepotentialofhydroxychloroquineagainstcovid19 AT annelisebienvenu coalitionadvocacyforprospectiveclinicaltrialstotestthepostexposurepotentialofhydroxychloroquineagainstcovid19 AT lucillehblumberg coalitionadvocacyforprospectiveclinicaltrialstotestthepostexposurepotentialofhydroxychloroquineagainstcovid19 AT jeandupouycamet coalitionadvocacyforprospectiveclinicaltrialstotestthepostexposurepotentialofhydroxychloroquineagainstcovid19 AT pierrecarnevale coalitionadvocacyforprospectiveclinicaltrialstotestthepostexposurepotentialofhydroxychloroquineagainstcovid19 AT shigeyukikano coalitionadvocacyforprospectiveclinicaltrialstotestthepostexposurepotentialofhydroxychloroquineagainstcovid19 AT malcolmkjones coalitionadvocacyforprospectiveclinicaltrialstotestthepostexposurepotentialofhydroxychloroquineagainstcovid19 AT claudiotadeudanielribeiro coalitionadvocacyforprospectiveclinicaltrialstotestthepostexposurepotentialofhydroxychloroquineagainstcovid19 AT santiagomascoma coalitionadvocacyforprospectiveclinicaltrialstotestthepostexposurepotentialofhydroxychloroquineagainstcovid19 |